{"organizations": [], "uuid": "3f423353b9f37841de0e62c0ebc36f1d74d0441f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/sangamo-deals-gilead-sciences/gilead-signs-3-bln-licensing-deal-for-sangamos-gene-editing-platform-idUSL4N1QC3GL", "country": "US", "domain_rank": 408, "title": "Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T20:21:00.000+02:00", "replies_count": 0, "uuid": "3f423353b9f37841de0e62c0ebc36f1d74d0441f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/sangamo-deals-gilead-sciences/gilead-signs-3-bln-licensing-deal-for-sangamos-gene-editing-platform-idUSL4N1QC3GL", "ord_in_thread": 0, "title": "Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "savio", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gilead", "sentiment": "negative"}, {"name": "gilead sciences inc", "sentiment": "negative"}, {"name": "sangamo", "sentiment": "negative"}, {"name": "sangamo therapeutics inc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc’s gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.\nSangamo will receive an upfront payment of $150 million and is eligible to receive up to $3.01 billion in potential payments, the companies said in a joint statement. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D‘Souza)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T20:21:00.000+02:00", "crawled": "2018-02-23T15:59:36.007+02:00", "highlightTitle": ""}